Le Lézard
Classified in: Health, Science and technology
Subject: MAT

Aesthetics Biomedical's Best-In-Class Vivacetm RF Microneedling Treatment Named a 2020 Most Worth It Procedure by RealSelf


PHOENIX, Feb. 3, 2020 /PRNewswire-PRWeb/ -- RealSelf, the go-to destination to assist consumers in making cosmetic treatment decisions and connecting with doctors, published its 2020 Most Worth It Ranking. The industry leading Vivacetm Microneedle RF device is the only microneedling treatment to earn the "Most Worth It" honor, bestowed to only 15 nonsurgical procedures on this year's list.

Vivacetm, FDA-cleared, is the newest generation of radio frequency microneedling. This minimally-invasive treatment stimulates the natural production of collagen and has been shown by physicians to be effective in alleviating facial wrinkles, fine lines, and tightening and toning the face, neck, hands, and body. Uniquely designed for an incomparable, comfortable patient experience, only Vivacetm boasts a precision robotic motor that brings discomfort to a virtual zero compared to any other device in physicians' offices.

The annual RealSelf Most Worth It Ranking identifies the Most Worth Ittm procedures1 of the year, determined by Worth It Ratings shared by real patients on RealSelf. The RealSelf Worth It Rating is a proprietary consumer satisfaction score based on reviews from consumers on RealSelf who, after undergoing a treatment, rated it as "Worth It" or "Not Worth It."

"It's truly an honor to receive the "Most Worth It" recognition for our best-in-class Vivacetm RF Microneedling device because it's earned from the testimonials of real patients. Striving to innovate the patient experience is the principle that Aesthetics Biomedical was founded on, so to have a coveted spot on this list is, in a way, the ultimate testimonial. We are consistently propelled by our mission to continually revolutionize the aesthetic industry for both patients and providers alike," says MaryAnn Guerra, Aesthetics Biomedical President and CEO.

"With more than 600 aesthetic procedures featured on RealSelf, consumers look to our annual list of Most Worth It procedures to easily discover and compare top-rated options," said Tom Seery, RealSelf founder and CEO. "There's nothing complicated or opaque about our algorithm?our ranking is based solely on Worth It Ratings shared by real patients, and that's why consumers trust it."

To be recognized as a 2020 Most Worth It procedure, a treatment must meet the minimum requirement of 50 reviews between January 1, 2019, and December 31, 2019, and have earned a cumulative Worth It Rating of 90% or higher during the same time period. For more information on the 2020 Most Worth It Ranking, please visit http://www.realself.com/news/most-worth-it-2020.

About Aesthetics Biomedical
Aesthetics Biomedical, Inc., headquartered in Phoenix, Ariz., is committed to the development and distribution of novel aesthetic devices, products, and services in the global market. Aesthetics Biomedical's innovation center is a leader in breakthrough technologies and combination therapies for its clients, physician network and the aesthetic arena, creating novel patient treatment experiences that benefit from ongoing research, approved clinical indications for use, as well as a personalized approach designed for consumer benefit. Visit AestheticsBiomedical.com

About RealSelf
RealSelf is the go-to destination for making cosmetic treatment decisions and connecting with doctors. Millions of people from around the world count on RealSelf to find unbiased information, real patient reviews and photos, treatment costs and ratings, and Verified doctors. From medical-grade skin care to emerging noninvasive technologies to highly considered cosmetic surgeries, RealSelf makes it easy to get the trusted insights you need to make smart, confident decisions about modern beauty treatments and doctors. For more information, visit RealSelf News and follow us on Instagram, Facebook and Pinterest.

1 To be recognized as a Most Worth It procedure, a treatment must have a cumulative Worth It Rating of 90% or more over the prior 12 months and meet the minimum review requirement of 50 reviews during the same period.

Methodology
To be recognized as a 2020 Most Worth It procedure, a treatment must meet the minimum requirement of 50 reviews between January 1, 2019, and December 31, 2019, and have earned a cumulative Worth It Rating of 90% or higher during the same time period. A total of 15 nonsurgical and 37 surgical procedures earned a Most Worth It designation for 2020. While treatment Worth It Ratings in the 2020 Most Worth It Ranking are shown as rounded percentages, the actual ranking is determined by several decimal places.

 

SOURCE Aesthetics Biomedical


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: